Pharmacotherapy for Disorders of Consciousness: Are ‘Awakening’ Drugs Really a Possibility?

• Published in: Drugs (New York, N.Y.) N.Y.), 2013-11, Vol.73 (17), p.1849-1862
• Main Authors: Ciurleo, Rosella, Bramanti, Placido, Calabrò, Rocco Salvatore
• Format: Article
• Language: English
• Subjects: Antidepressive Agents - pharmacology; Biological and medical sciences; Coma; Consciousness; Consciousness - drug effects; Consciousness Disorders - drug therapy; Consciousness Disorders - physiopathology; Disorders of higher nervous function. Focal brain diseases. Central vestibular syndrome and deafness. Brain stem syndromes; Dopamine Agents - pharmacology; Drug Design; Drugs; gamma-Aminobutyric Acid - metabolism; Humans; Internal Medicine; Leading Article; Medical sciences; Medicine; Medicine & Public Health; Nervous system (semeiology, syndromes); Neurology; Neurons; Neurotransmitter Agents - metabolism; Persistent Vegetative State - drug therapy; Persistent Vegetative State - physiopathology; Pharmacology/Toxicology; Pharmacotherapy; Traumatic brain injury
• ISSN: 0012-6667; 1179-1950
• DOI: 10.1007/s40265-013-0138-8

Disorders of consciousness, including the coma state, vegetative state and minimally conscious state, are among the least understood and least curable conditions in modern neurology. Structural or functional injuries may produce impairments in the neuronal circuits (the ascending reticular activating system and thalamocortical loops) responsible for maintaining the wakefulness state and awareness, associated with a change in neurotransmitter concentrations. Pharmacological agents that are able to restore the levels of neurotransmitters and, consequently, neural synaptic plasticity and functional connectivity of consciousness networks, may play an important role as drugs useful in improving the consciousness state. Currently, there is growing interest in the scientific community with regard to pharmacological agents that act on the gamma amino-butyric acid (GABA) system, such as zolpidem and baclofen, and monoamine systems, such as dopaminergic agents and some antidepressants. The purpose of this article is to provide a comprehensive overview of these potential ‘awakening’ drugs in patients with disorders of consciousness. The possible mechanisms by which these drugs may exert their effects in promoting recovery of consciousness are discussed, highlighting how many findings are often the result of sporadic events rather than prospective controlled trials or implementation of standard treatment guidelines.